Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How JAZZ Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | 44% | -10.1% | -$356.1M | $1.30B | -4.7% |
| FY 2024 | $4.07B | 44% | 17.6% | $560.1M | $1.36B | 7.3% |
| FY 2023 | $3.83B | 44% | 15.1% | $414.8M | $919.5M | 10.2% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring JAZZ)
- ✓Live walkthrough of JAZZ's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
JAZZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +4.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on JAZZ today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for JAZZ. Explore sector supply chains on /butterfly.
JAZZ Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ)?
In FY 2025 (10-K), JAZZ converted $4.3B of revenue into a 44% gross margin, 0% operating margin, and $1.3B in free cash flow (30.4% FCF margin).